Individuals diagnosed with major depression who have anxiety symptoms may be able to participate in an NIMH research study that seeks to decrease symptoms of depression and understand the causes of anxious depression. Anxiety symptoms may include tension, worry, apprehension, restlessness, or loss of appetite. This study evaluates the effectiveness and safety of the study drug AZD2327 in the treatment of major depression and anxiety symptoms. This drug has a different mechanism of action from commonly used selective serotonin reuptake inhibitors for anxiety and depression. This is a 12-week outpatient study, including an inpatient stay of four days in Bethesda, MD. Individuals 18-65 years of age who have been diagnosed with major depression and have anxiety symptoms may be eligible for this clinical trial. There is the chance of receiving placebo in this study. After completion of the study, NIMH will provide short-term follow-up care, and then the individual will return to the care of their own provider. In addition, all research participation is without cost and NIMH will cover all transportation costs from anywhere in the United States.
Ages Eligible for Study: 18 Years to 65 Years
Provision of informed consent prior to any study specific procedures
A history of substance or alcohol abuse within the past 6 months or dependence within 1 year of enrollment as defined by DSM-IV criteria.
Women that are pregnant or lactating
History of pancreatitis